Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 800
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
详细描述
inclusion criteria Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer EGFR G719X, exon 20 insert mutation without any anti-cancer treatment history
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- •Uncommon EGFR Mutant Advanced NSCLC
排除标准
- •Patients with contraindication of chemotherapy
- •Pregnant or breast feeding women
研究组 & 干预措施
Cohort 7 Compound Mutations Uncommon With Common
patients with compound mutations uncommon with common
干预措施: EGFR-TKI (Drug)
Cohort 1 Uncommon EGFR exon 19del
patients with uncommon EGFR exon 19del
干预措施: Third-generation EGFR-TKI (Drug)
Cohort 2 EGFR exon 19delins
patients with EGFR exon 19delins
干预措施: Third-generation EGFR-TKI (Drug)
Cohort 3 EGFR exon 18del
patients with EGFR exon 18del
干预措施: EGFR-TKI (Drug)
Cohort 4 Common Uncommon Point Mutations
patients with common uncommon point mutations
干预措施: EGFR-TKI (Drug)
Cohort 5 Rare Uncommon Point Mutations
patients with rare uncommon point mutations
干预措施: EGFR-TKI (Drug)
Cohort 6 Compound Mutations Uncommon With Uncommon
patients with compound mutations uncommon with uncommon
干预措施: EGFR-TKI (Drug)
结局指标
主要结局
PFS
时间窗: 5 years
Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)
次要结局
- OS(5 years)
- ORR(5 years)
研究者
Yongchang Zhang
professor
Hunan Province Tumor Hospital